Answers are grounded in this paper and cite their sources.
, demonstrating a potency which is a thousand times greater than traditional PDE4 inhibitors. In addition, the PDE4B/D degrader (BTX-AP02) efficiently degrades PDE4D in the spleens of treated mice in a dose-dependent manner, with no significant adverse effects at dose levels used in the study. We also demonstrate the efficacy of our lead oral PDE4B/D degrader (BTX-AP04) in a mouse model of graft-versus-host disease (GvHD). Notably, our PDE4D degraders exhibit minimal degradation of known neo-substrates of cereblon (CRBN), indicating high specificity. Taken together, we propose the introduction of a more potent, specific, and safe PDE4B/D degrader as a novel treatment for inflammatory skin conditions such as AD.
No takes yet. Share an insight, caveat, or question.
Shakya et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: